中化化肥(00297.HK):中化香港完成轉讓52.65%股份予中農科技
格隆匯6月17日丨中化化肥(00297.HK)公告,內容關於公司在轉讓前的控股股東中化香港以1美元的總代價將其持有的3,698,660,874股股份(約佔公司已發行股總額的52.65%)轉讓予中農科技(該公司名稱已變更為先正達集團股份有限公司)或其一個或多個關聯方。
於2020年6月17日,公司獲中化香港告知其已完成了轉讓。轉讓後,中國農化(香港)控股有限公司(一家根據香港法律註冊成立的有限公司,併為中國化工的間接全資附屬公司且為先正達集團的關聯方)將成為該3,698,660,874股股份(約佔公司已發行股總額的52.65%)的法定實益擁有人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.